idp-023
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 25, 2023 (NCT06119685)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Autoimmune Diseases · Phase 1
- Autoimmune Diseases of the Nervous System · Phase 1
- Demyelinating Autoimmune Diseases, CNS · Phase 1
- Demyelinating Diseases · Phase 1
- Immune System Diseases · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Multiple Sclerosis · Phase 1
- Multiple Sclerosis, Chronic Progressive · Phase 1
- Neoplasms · Phase 1/Phase 2
- Nervous System Diseases · Phase 1
Mechanism of action
- Natural killer cellImmunity, passive
Natural killer cell immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06677710 | Phase 1 | Nov 1, 2024 | Indapta Therapeutics, INC. |
| NCT06119685 | Phase 1/Phase 2 (Phase 2) | Oct 25, 2023 | Indapta Therapeutics, INC. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Indapta Therapeutics, INC. | For profit | 2 | 2 | 2 | 2023 |
1 organizations
Page 1 / 1